Company intelligence
N-Power Medicine, Inc.
Accelerating Oncology Innovation
About N-Power Medicine, Inc.
N-Power Medicine is developing a radically faster, smarter paradigm for drug development that enables biopharma to move beyond traditional randomized clinical trials. Through a network of community oncology practices and proprietary infrastructure, N-Power has built a next-generation platform where every cancer patient can participate in research, either as a trial participant or as part of a regulatory-grade Prospective External Control Arm (ProECA). Powered by the Kaleido™ Registry and ProECA platform, N-Power’s model reduces reliance on randomization, cuts years off development timelines, and saves hundreds of millions of dollars per program. N-Power is expanding access to clinical trials and redefining what’s possible in cancer drug development.
Verified activity
Signals from N-Power Medicine, Inc.
3 published signals
Customers & Market
N-Power Medicine, Inc. launched its first Prospective External Control Arms program in NSCLC across more than 30 sites.
Reported by Mark Lee
Customers & Market
N-Power Medicine, Inc. is launching colorectal and prostate Prospective External Control Arms programs later this year.
Reported by Mark Lee
Capital & Finance
N-Power Medicine, Inc. closed a $32 million Series B funding round with new strategic investment from Labcorp Venture Fund.
Reported by Mark Lee